| DEFINIUM THERAPEUTICS |
| Kanada |
| Gesundheit |
| CA24477V1058 / A420P3 |
| MMQ0 (Frankfurt) / DFTX (NASDAQ) |
| FRA:MMQ0, ETR:MMQ0, MMQ0:GR, NASDAQ:DFTX |
| - |
| https://definiumtx.com/ |
|
Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for psychiatric and neurological disorders. Headquartered in New York City, the company applies scientific rigor to psychedelic-based m..
>Volltext.. |
| 5250.37 Mio. EUR |
| 4334.36 Mio. EUR |
| - |
| -196.93 Mio. EUR |
| -306.18 Mio. EUR |
| -2.98 EUR |
| 31.56 Mio. EUR |
| 567.1 Mio. EUR |
| -144.31 Mio. EUR |
| 6.89 |
| - |
| -218.66% |
| - |
| - |
| - |
| - |
| DEFINIUM |
| 12.08.26 |
|